QualityStocks would like to highlight Advaxis (http://www.qualitystocks.net/stocks1.html">OTCBB:ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news,
Advaxis announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have been given the inaugural University of Pennsylvania One Health Award for their research of Advaxis’ proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma.
The One Health Award, a new accolade for excellence in promoting One Health initiatives and inter-professional education, was established this year by the deans of the four health schools at Penn – Medicine, Nursing, Veterinary Medicine, and Dental Medicine. The award recognizes exemplary contributions toward expanding interdisciplinary education and improving health care.
“Dr. Paterson and I are delighted to have received the One Health Award for our work using ADXS-cHER2 to prevent metastatic disease in dogs with osteosarcoma. Phase 1 of this clinical trial is almost complete and we have been highly encouraged by the lack of adverse effects of this treatment,” stated Dr. Nicola Mason, Chair in Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine. “It is too early to comment on the efficacy of the immunotherapy, however, we are encouraged by the data we have obtained so far and are optimistic that immunotherapies such as this one will provide safer and more effective treatment for dogs with cancer in the near future.”
ADXS-cHER2, under the direction of Dr. Nicola Mason, is being used to treat dogs suffering from bone cancer. In this trial, dogs that have undergone standard of care treatment for osteosarcoma; including limb amputation and follow up chemotherapy, and that overexpress the tumor marker HER-2/neu in their tumors, are treated with ADXS-cHER2. This immunotherapy is designed to stimulate the dog’s immune system to attack cancer cells that express the HER-2/neu marker. The goal is to elicit anti-tumor immunity and prolong survival.
Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. The current standard of care is immediate amputation followed by chemotherapy; however, the cancer typically metastasizes, most commonly to the lungs, and causes death in 6-12 months in a percentage of afflicted dogs.
“The award winning research of Dr. Mason and Dr. Paterson establishes that the Advaxis platform technology can be extended to veterinary use,” commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. “Data from this project will support the further development of our HER-2 targeted immunotherapy against HER-2 overexpressing malignancies in both veterinary and possibly human cancers.”
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.